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PROTOCOLS
Manufacture of Third-Generation Lentivirus for Preclinical Use,
with Process Development Considerations for Translation
to Good Manufacturing Practice
Carolina Ga´ndara,1,2 Valerie Affleck,1,2 and Elizabeth Ann Stoll1,2,*
1Institute of Neuroscience and 2Controlling Abnormal Network Dynamics using Optogenetics (CANDO) Consortium, Newcastle University,
Newcastle upon Tyne, United Kingdom.
Lentiviral vectors are used in laboratories around the world for in vivo and ex vivo delivery of gene ther-
apies, and increasingly clinical investigation as well as preclinical applications. The third-generation len-
tiviral vector system has many advantages, including high packaging capacity, stable gene expression in
both dividing and post-mitotic cells, and low immunogenicity in the recipient organism. Yet, the manu-
facture of these vectors is challenging, especially at high titers required for direct use in vivo, and further
challenges are presented by the process of translating preclinical gene therapies toward manufacture of
products for clinical investigation. The goals of this paper are to report the protocol for manufacturing high-
titer third-generation lentivirus for preclinical testing and to provide detailed information on considerations
for translating preclinical viral vector manufacture toward scaled-up platforms and processes in order to
make gene therapies under Good Manufacturing Practice that are suitable for clinical trials.
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INTRODUCTION
THE THIRD-GENERATION lentiviral vector design and
original protocol for high-titer virus production was
developed in the Naldini and Trono laboratories.1–3
In the 20 years since, lentiviral vectors have become
commonly used for gene delivery for preclinical re-
search applications and are now becoming the vector
of choice for in vivo and ex vivo delivery of genetic
material in gene and cell therapies,4,5 having been
madeandused forclinical trials inhumanpatients.6–9
This gene therapy delivery system is well-
characterized, effectively delivers genetic material
into dividing and nondividing cells, stably integrates
into the host cell genome to maintain long-term ex-
pression in target cells, and delivers larger amounts
of genetic material than other vector systems. Fur-
thermore, third-generation lentiviruses are thought
to be nonpathogenic and non-immunogenic, al-
though long-term investigations are still underway.
Guidance on broaching this and related subjects
with regulatory authorities in the course of devel-
oping a clinical trial plan is available.10
The third-generation lentiviral vectors de-
scribed here are considered to be replication-
incompetent and self-inactivating vectors, due to
the number of essential genes that have been de-
leted from the third-generation lentiviral packag-
ing system.11 These third-generation lentivector
systems have a number of additional safety fea-
tures over the second-generation: the viral tat gene,
which is essential for replication of wild-type hu-
man immunodeficiency virus type 1 (HIV-1), has
been deleted; vector packaging functions have been
separated onto three separate plasmids instead of
two in order to reduce risk of recombination during
plasmid amplification and viral vector manufac-
ture; an altered 3¢ LTR renders the vector ‘‘self-
inactivating’’ in order to prevent integrated genes
from being repackaged; and a heterologous coat
protein (e.g., VSV-G) is used in place of the native
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HIV-1 envelope protein. VSV-G is the most popular
glycoprotein to date for pseudotyping lentiviral
vectors, as these modified particles can transduce a
wider range of cell types and have a lot more sta-
bility, which allowed these vectors to be concentrated
by ultracentrifugation to reach higher titers.12
Preclinical gene therapies made with substantially
similar lentiviral vectors to the clinical material can
be used for efficacy testing in various model systems,
in vitro and in vivo. Protocols for small-scale pro-
duction of second-generation lentiviral vectors,13,14 as
well as more general manufacturing reviews15 and
large-scale Good Manufacturing Practice (GMP)-
grade methods16–22 have been published. This report
provides a useful, open-access protocol for the pro-
duction of high-titer third-generation lentivirus, with
tips for translating preclinical research-grade pro-
cedures toward GMP for the production of viral-
mediated gene therapies for clinical investigation. In
this protocol, HEK293T are used as producer cells,
but COS-7 cells have also been successfully used for
lentiviral manufacture.14
The goals of this report are to share the Standard
Operating Protocol (SOP) for preclinical lentivirus
production and the process development consider-
ations for clinical-grade lentivirus manufacture,
where the quality of the product, consistent pro-
duction, and GMP compliance must be met, as well
as the requirements set in the relevant manufactur-
ing and clinical trial authorizations. A broad overview
of processes related to the manufacture of GMP
lentiviral vector-based gene therapies is shown in
Fig. 1; specific considerations for converting pre-
clinical viral manufacturing protocols and platforms
to scaled-up GMP manufacture are provided after
the protocol itself and the troubleshooting section.
MATERIALS
HEK293T producer cell line
HEK 293 cells were generated in 1973 by isola-
tion and subsequent adenoviral-mediated trans-
formation of human embryonic kidney cell cultures
in Alex van der Eb’s laboratory in Leiden, The
Netherlands. The 293T cells are derived from
HEK 293 cells but stably express the SV40 large T
antigen, which can bind to SV40 enhancers-of-
expression vectors to increase protein production.
Figure 1. Process for lentiviral production under Good Manufacturing Practice.
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This cell line is easy to grow, transfects readily,
ectopically expresses genes, and has been widely
used in research laboratories for many years.
HEK293T are also used as cell factories to gen-
erate lentiviral vectors23 (as described here in
‘‘Experimental Procedures’’).
Plasmids encoding the genetic payload
and viral packaging components
The transfer vector should contain the desired
transgene(s) and other components required for vi-
ral integration and expression in the host genome.
The full sequence justification of pMUH, a versatile
third-generation lentivector,10 is given in Table 1.
This and similar third-generation lentivector trans-
fer plasmids contain multiple cloning sites for in-
sertion of target genes, as well as a fluorescent
reporter or selection marker for preclinical use.
Using this vector plasmid, the promoter driving
gene expression, and up to three genes, can easily be
swapped to achieve flexibility for preclinical viral
vector development and to achieve the leanest len-
tivector construct sequence for producing a targeted
gene therapy.
It is inadvisable for fluorescent reporter proteins
to be included in viral vectors used for gene ther-
apies in humans, since these proteins are thought
to be immunogenic.24 However, efficacy tests in cell
cultures or animal models can make use of them.
Furthermore, European regulatory guidance urges
Table 1. pMUH third-generation lentivector plasmid
Location Size (bp) Feature Description and justification
8. 234 227 RSV promoter Essential for gene expression during viral vector manufacture.
235. 415 181 5¢ LTR (truncated) Truncated 5¢ LTR from HIV-1. Essential for viral transcription, reverse transcription, and
integration.
462. 587 126 HIV-1 C Packaging signal of HIV-1. Essential for transfer plasmid packaging.
1080. 1313 234 RRE Essential for Rev-dependent mRNA export from the nucleus to the cytoplasm of viral
transcripts.
1840. 1957 118 cPPT/CTS cPPT/CTS of HIV-1. Improves vector integration and transduction efficiency.
2022. 3233 1,212 UbC promoter Promoter that drives ubiquitous expression of the transgenes. Can be replaced by cell-type
specific promoters.
3272. 3979 708 mCherry monomeric derivative of DsRed fluorescent protein. Indicates transgene expression. Can
be replaced or removed for clinical trials.
3989. 4045 57 P2A 2A peptide from porcine teschovirus-1 polyprotein. Self-cleaving peptide to separate co-
expressed proteins. Can be replaced or removed for clinical trials.
4052. 4087 36 MCS Contains multiple restriction sites used for transgenes insertion.
4097. 4150 54 T2A 2A peptide from Thosea asigna virus capsid protein. Self-cleaving peptide to separate co-
expressed proteins. Can be replaced or removed for clinical trials.
4194. 4782 589 WPRE Improves transgene expression by facilitating mRNA transcript maturation.
4873. 5106 234 3’ LTR (DU3) self-inactivating 3¢ LTR from HIV-1. Essential for viral transcription, reverse transcription
and integration. Contains a safety measure to prevent viral replication.
5178. 5299 122 SV40 poly(A) signal Important for the nuclear export, translation, and stability of mRNA.
5339. 5474 136 SV40 ori Essential for transfer plasmid maintenance in mammalian cells during viral vector
manufacture.
5495. 5513 19 T7 promoter Promoter for bacteriophage T7 RNA polymerase. Plasmid features.
5523. 5539 17 M13 fwd Common sequencing primer, one of multiple similar variants. Used for sequencing
purposes.
5681. 6136 456 f1 ori Arrow indicates direction of (+) strand synthesis. Plasmid features.
6162. 6266 105 AmpR promoter Ampicillin resistance gene promoter for plasmid selection in bacteria; will be substituted
for clinical-grade plasmid per EMA NOTE CPMP/BWP/3088/99 and Ph. Eur., Monograph
5.14.
6267. 7127 861 AmpR Ampicillin resistance selectable marker for plasmid selection in bacteria; will be
substituted for clinical-grade plasmid per EMA NOTE CPMP/BWP/3088/99 and Ph. Eur.,
Monograph 5.14.
7298. 7886 589 ori High-copy-number ColE1/pMB1/pBR322/pUC origin of replication. Essential for plasmid
replication in bacteria.
8174. 8195 22 CAP binding site Trans-acting transcriptional activator. Plasmid features.
8210. 8240 31 lac promoter Promoter for the Escherichia coli lac operon. Plasmid features.
8248. 8264 17 lac operator Repression region for the E. coli lac operon. Plasmid features.
8272. 8288 17 M13 rev Common sequencing primer, one of multiple similar variants. Used for sequencing
purposes.
8309. 8327 19 T3 promoter Promoter for bacteriophage T3 RNA polymerase. Plasmid features.
RSV, Rous sarcoma virus; LTR, long terminal repeat; HIV-1, human immunodeficiency virus type 1; RRE, Rev response element; cPPT/CTS, central polypurine
tract and central termination sequence; UbC, human ubiquitin C promoter; MCS, multiple cloning site; WPRE, woodchuck hepatitis virus posttranscriptional
regulatory element; SV40 poly(A) signal, SV40 polyadenylation signal; SV40 ori, Simian virus 40 (SV40) origin of replication; f1 ori, f1 bacteriophage origin of
replication.
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careful and well-justified use of antibiotics during
plasmid preparation and viral production in order
to avoid the cultivation of antibiotic-resistant strains
of bacteria. Such considerations should be taken into
account when designing the specific characteristics
of a transfer vector.
Packaging plasmids
The packaging genes used for preclinical third-
generation lentivirus manufacture are contained
on three separate plasmids, which are co-transfected
into the producer cell line along with the transfer
vector. These three plasmids are described in
Tables 2–4. The four plasmids are shared among
academic laboratories, but would have to be spe-
cifically licensed for use in clinical-grade lentivirus
manufacture.
pRSV-Rev (Addgene #12253,
from the laboratory of Prof. Didier Trono)
The sequence of the pRSV-Rev plasmid is de-
scribed in Table 2. This is a cDNA expressing plas-
mid in which the joined second and third exons of
HIV-1 rev is under the transcriptional control of RSV
U3 promoter.Rev is a trans-activating protein that is
essential to the regulation of HIV-1 protein expres-
sion. A nuclear localization signal is encoded in the
rev gene, which allows the Rev protein to be trans-
ported to the nucleus, where it is involved in the
export of unspliced and incompletely spliced mRNAs.
In the absence of rev, mRNAs of the HIV-1 late
(structural) genes are retained in the nucleus, pre-
venting their translation. HIV-1 regulatory proteins
(including rev) are translated from completely pro-
cessed mRNA transcripts, while structural proteins
are translated from incompletely spliced transcripts.
Completely spliced transcripts are exported from the
nucleus to the cytoplasm by the same mechanism as
cellular mRNA. However, rev is needed to export
incompletely spliced mRNAs in order to produce the
viral structural proteins during manufacture.
pMD2.G (Addgene #12259,
from the laboratory of Prof. Didier Trono)
The sequence of the pMD2.G plasmid encoding
Vesicular stomatitis virus glycoprotein is described
in Table 3. This cDNA expressing plasmid encodes
vesicular stomatitis virus glycoprotein (vsv-g) to
coat the envelope of the virus, providing a tropism
that allows entry into a broad range of mammalian
cell types. Alternative envelopes for lentiviral vec-
tors other than VSV-G have been proposed. The use
of different envelopes can be a powerful tool to
achieve cell-specific gene delivery.25
Table 2. pRSV-Rev packaging plasmid
Location Size (bp) Feature Description and Justification
1024. 1612 589 ori High-copy-number ColE1/pMB1/pBR322/pUC origin of replication. Essential for plasmid replication in
bacteria.
1900. 1921 22 CAP binding site Trans-acting transcriptional activator. Plasmid features.
1936. 1966 31 lac promoter Promoter for the E. coli lac operon. Plasmid features.
1974. 1990 17 lac operator Repression region for the E. coli lac operon. Plasmid features.
1998. 2014 17 M13 rev Common sequencing primer, one of multiple similar variants. Used for sequencing purposes.
2159. 2420 262 RSV promoter Essential for Rev expression.
2549. 2899 351 Rev Trans-activating protein to control nuclear export of incompletely spliced mRNAs. Essential to produce
viral structural proteins during viral vector manufacture.
2983. 2999 17 M13 fwd Common sequencing primer, one of multiple similar variants. Used for sequencing purposes.
3331. 3786 456 f1 ori f1 bacteriophage origin of replication; arrow indicates direction of (+) strand synthesis. Plasmid
features.
4068. 4172 105 AmpR promoter Ampicillin resistance gene promoter. Essential for plasmid selection in bacteria.
4173. 853 861 AmpR Ampicillin resistance selectable marker. Essential for plasmid selection in bacteria.
Table 3. pMD2G packaging plasmid
Location Size (bp) Feature Description and justification
1048. 1442 395 b-globin poly(A) Important for the nuclear export, translation, and stability of mRNA.
1952. 2540 589 ori High-copy-number ColE1/pMB1/pBR322/pUC origin of replication. Essential for plasmid replication in bacteria.
2711. 3571 861 AmpR Ampicillin resistance selectable marker. Essential for plasmid selection in bacteria.
3572. 3676 105 AmpR promoter Ampicillin resistance gene promoter. Essential for plasmid selection in bacteria.
3867. 4246 380 CMV enhancer Human CMV immediate early enhancer. Essential for Rev expression.
4247. 4450 204 CMV promoter Human CMV immediate early promoter. Essential for Rev expression.
4584. 5059 476 b-globin intron Internally truncated intron from human b-globin. Improves gene expression.
5134. 847 1536 VSV-G Replaces the native lentiviral Env glycoprotein, providing more stable vectors to transduce a wider set of cells.
b-globin poly(A), human b-globin polyadenylation signal; CMV, cytomegalovirus; VSV-G, vesicular stomatitis virus G glycoprotein.
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pMDLg/pRRE (Addgene #12251,
from the laboratory of Prof. Didier Trono)
The sequence of the pMDLg/pRRE plasmid en-
coding viral core proteins is described in Table 4. This
plasmid encodes gag, which encodes the main struc-
tural proteins of the virus, andpol, which encodes the
retrovirus-specific enzyme reverse polymerase.
Reagents and consumables
Reagents used in preclinical manufacture are
shown in Supplementary Table S1 (Supplementary
Data are available online at www.liebertpub.com/
hgtb). Many of these products are made or steril-
ized under high-quality conditions, traced from
origin, and certified for GMP use.
Consumables, such as conical tubes and tissue
culture flasks, used in preclinical virus manufac-
ture, which are made or sterilized under high-
quality conditions, traced from origin, and certified
for GMP use, are suitable for use in GMP manu-
facture as well as for research purposes.
Instrumentation and equipment
1. Small incubator 37C
2. Large orbital shaker/incubator
3. Bunsen burner
4. Microwave
5. Balance
6. pH meter
7. Gel electrophoresis and imaging system
8. Blue light transilluminator
9. Vortex mixer
10. DNA spectrophotometer
11. Biological safety cabinet
12. CO2 system
12.1. Tanks
12.2. Regulators
12.3. Hoses
12.4. Changeover unit
13. Incubator 37C, 5% CO2
14. Benchtop centrifuges
14.1. Mini (pulse spin, 1.5 mL tubes)
14.2. Micro (1.5 mL tubes)
14.3. Small (50 mL tubes)
15. Ultracentrifuge
16. Refrigerator (4C)
17. Freezers (-20C and -80C)
18. N2 storage tank
19. Light microscope
20. Bead or water bath
21. Vacuum pump
22. Pipettes
EXPERIMENTAL PROCEDURE
Making reagents for cell culture
and transfection
Cell culture medium (containing 10% fetal bovine
serum). In 440 mL of Dulbecco’s modified Eagle’s
medium containing high glucose, add 50 mL of fetal
bovine serum (FBS; for a final concentration of 10%),
5 mL of 200 mM L-glutamine (for a final concentra-
tion of 2 mM), 5 mL of 100 mM sodium pyruvate (for
a final concentration of 1 mM), and 5 mL of 10,000
IU/mL penicillin/streptomycin solution (for a final
concentration of 100 IU/mL). Store at 4C.
Calcium chloride transfection reagent (CaCl2
2.5M). Dissolve 36.75 g of calcium chloride dehy-
drate in 100 mL MilliQ/PureLab Flex2 water. Ster-
ilize by filtration with a 0.45lm filter (Millipore).
Store 1.5 mL aliquots for up to 6 months at -20C.
Working concentrations of CaCl2 are obtained by
diluting the stock concentration in deionized tissue-
culture-grade water (e.g., 80lL of 2.5 M CaCl2 to
920lL dH2O, to achieve 0.20 M final concentration).
Borate-buffered saline transfection reagent (BBS
2 · ). Dissolve 4.09 g of NaCl, 2.6625 g of BES,
Table 4. pMDLg/pRRE packaging plasmid
Location Size (bp) Feature Description and justification
22. 401 380 CMV enhancer Human CMV immediate early enhancer. Essential for Rev expression.
402. 605 204 CMV promoter Human CMV immediate early promoter. Essential for Rev expression.
739. 1214 476 b-globin intron Internally truncated intron from human b-globin. Improves gene expression.
1298. 2800 1503 HIV-1 gag gag protein from HIV-1. Encodes essential viral core proteins.
2593. 5604 3012 HIV-1 pol pol protein from HIV-1. Encodes a set of enzymes essential for viral integration.
5289. 5406 118 cPPT/CTS Improves vector integration and transduction efficiency.
5629. 5862 234 RRE Essential for Rev-dependent mRNA export from the nucleus to the cytoplasm of viral transcripts.
6093. 6487 395 b-globin poly(A) Important for the nuclear export, translation and stability of mRNA.
6997. 7585 589 ori High-copy-number ColE1/pMB1/pBR322/pUC origin of replication. Essential for plasmid replication in bacteria.
7756. 8616 861 AmpR Ampicillin resistance selectable marker. Essential for plasmid selection in bacteria.
8617. 8721 105 AmpR promoter Ampicillin resistance gene promoter. Essential for plasmid selection in bacteria.
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and 0.0525 g of Na2HPO4; add deionized tissue-
culture-grade water to reach a volume of 250 mL.
Adjust pH to 6.95. Sterilize by filtration with a
0.45 lm filter (Millipore). Store 14 mL aliquots for
up to 6 months at -20C.
Expanding HEK293T cell line for viral
production by reanimation and passaging
1. Remove a vial of HEK293T expanded mas-
ter cell line stored at -20C.
2. Thaw at 37C for approximately 2 min.
3. Add 1 mL of cells to 10 mL of cell culture
medium in a 50 mL conical tube.
4. Centrifuge two balanced conical tubes at
250 g for 4 min.
5. Re-suspend cells in 10 mL of cell culture
medium containing 10% FBS.
6. Count cells with a hemocytometer (for ap-
proximately 105 cells/mL).
7. Plate 10 mL of fresh cell culture medium–
containing cells into a 10 cm dish or equiv-
alent flask.
8. Place cells in the incubator at 37C and 5%
CO2 overnight.
9. When cells are 70% confluent, after 1–4 days,
they are ready for passage.
10. Remove the serum-containing medium and
rinse with phosphate-buffered saline (PBS).
Note: FBS inhibits the trypsin enzyme, so it
must be removed to allow this reaction.
11. Place trypsin-EDTA diluted in dPBS (1:10
or 0.05%) onto the cells and watch for signs
of dissociation.
Note: Lower concentrations of trypsin may
be gentler on the cells, but will require longer
incubation times or greater mechanical dis-
sociation.
12. Once cells have dissociated, they can be col-
lected and spun down.
Note: Cells should be further diluted in cell
culture medium containing 10% FBS.
13. The cell pellet should be re-suspended well
in approximately 2 mL of cell culture medi-
um.
14. The cells should then be further diluted in
an appropriate volume of cell culture me-
dium to plate the cells at 104–105 cells/mL.
Optimizing the transfection
Alternative transfection methods can be used for
larger lentiviral vector production volumes.26
1. Plate HEK293T cells in four 10 cm tissue
culture dishes.
2. Cells are ready for transfection at 70%
confluence, about 24 h after plating.
3. Thaw 2·BBS and 2.5 M of CaCl2 solutions
at room temperature.
4. Prepare different concentrations of CaCl2
(0.20 M, 0.25 M, 0.30 M, 0.35 M) in cell
culture-grade dH2O, by diluting 80 lL of
CaCl2 in 920 lL of dH2O and so on.
5. Place 10lg DNA (GFP control plasmid) into
each of four conical centrifuge tubes.
6. Add 500lL of diluted CaCl2 per tube.
7. Pipette gently up and down.
8. Add dropwise 500lL 2 ·BBS per tube.
9. Pipette gently up and down.
10. Let the reaction stand for 30 min at room
temperature in the hood.
11. Add the mixture drop by drop over each
dish. Cover the entire area of the dishes.
12. Place cells in the incubator at 37C and 3%
CO2 overnight.
13. Check the fluorescence under the micro-
scope after 24 h.
14. Determine which concentration gives the
best transfection efficiency; >95% of cells
should be green to achieve high levels of
viral production.
Plating HEK293T for production
of third-generation lentiviral vectors
Do not allow cells to grow over-confluent prior to
viral production; it will lower the titer.
1. To coat plates, prepare 20 cm dishes or
equivalent flasks.
2. Dilute 20 mL of poly-L-lysine in 80 mL of
dPBS.
3. Pipette 10 mL of this 1:5 PLL:dPBS solution
in each plate (10 · 20 cm).
4. Let plates stand for >15 min at room tem-
perature in the hood.
5. Aspirate. The plates are now coated. Plate
cells immediately after coating.
6. To plate cells, collect HEK293T from con-
fluent plates.
7. Remove media and wash 4· 20 cm confluent
plates with 6 mL of dPBS.
8. Add 4 mL of Trypsin-EDTA (0.5%) to each
plate, along with 6 mL of dPBS.
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9. Incubate at room temperature for 2 min or
until cells start to detach.
10. Add 10 mL culture medium and collect all
cells.
11. Centrifuge two balanced tubes of cells at
250 g for 4 min.
12. Re-suspend cells in 160 mL of culture me-
dium.
13. Count cells with a hemocytometer (the tar-
get is approximately 5· 105 cells/mL).
14. Plate 16 mL of fresh cell culture medium
containing cells into each dish. Place cells in
the incubator at 37C and 5% CO2 over-
night.
15. Cells are ready for transfection at 70%
confluence, about 24 h after plating.
Transfecting HEK293T to produce
third-generation lentiviral vectors
Transfection efficiency is a major factor in lenti-
viral vector yields. Plasmid DNA concentration and
quality, cell culture density, and pH variations of
BBS are some of the factors that can affect trans-
fection efficiency. If low transfection efficiency
(<60%) persists, addition of sodium butyrate within
24 h post transfection can potentially enhance pro-
tein expression levels.
1. Thaw 2·BBS and 2.5 M of CaCl2 solution at
room temperature.
2. Prepare proper concentration of CaCl2, as
previously determined for this batch of re-
agent.
3. Mix plasmids together, as described in Table 5.
4. Add 11 mL CaCl2 to the tube (for 10·15 cm
plates).
5. Pipette gently up and down.
6. Add dropwise 11 mL of 2·BBS to the tube
(for 10· 15 cm plates).
7. Pipette gently up and down.
8. Let the reaction stand for 30 min at room
temperature in the hood.
9. Add 2.25 mL of the mixture into each dish.
Cover the entire area of the dishes.
10. Place cells in the incubator at 37C and 3%
CO2 overnight.
Collecting virus-rich supernatants
 All waste that is possibly contaminated with
virus should be inactivated by incubation
with disinfectant for 30 min, and all of this
waste should be collected in dedicated bags.
These bags should be transferred to an auto-
clave using closed containers and inactivated
by autoclaving at 121C for 20 min.
 All autoclaved waste should be incinerated
using the appropriate clinical waste route
using an approved contractor.
 In the event of spillage of possibly viral vector-
contaminated material, the area will be disin-
fected using appropriate disinfectant. The used
paper towels and any other disposable mate-
rial should be collected in dedicated bags and
autoclaved as above. All work should be per-
formed in a contained area. The wider envi-
ronment is unlikely to become contaminated.
However, a plan should be in place for both a
contained spill and uncontained spill (e.g., in
an area with high foot traffic). A spill kit
should be available in the tissue culture unit
and in other areas of use (e.g., the surgery unit
if the virus will be used in vivo) for maximal
preparedness. Spill response cue cards, with
instructions and contact numbers in case of
accidental release, should be posted in the
manufacturing facilities.
1. After 18 h, replace the culture media with
16 mL of fresh cell culture medium.
2. Do not collect this transfection media (re-
move and dispose in appropriate contain-
ment).
3. Put cells back in the incubator at 37C and
3% CO2.
4. After 24 h, remove cell culture medium and
place it into four 50 mL conical tubes. This
Table 5. Plasmid quantities used to achieve transfection for viral production
DNA mass (lg) DNA length (bp) DNA copy number Plasmid volume (lL)
Transfer vector 300 7,537a 3.9 · 1013
DNA mass (lg)
plasmid concentration (lg=lL)
pMDLg/pRRE 250 8,890 2.7 · 1013
pRSV-Rev 125 4,180 2.9 · 1013
pMD2.G 150 5,822 2.5 · 1013
aThe transfer vector length will vary according to the transgene size. When using different plasmid lengths, the DNA copy number should be always
maintained as specified above, which can be achieved by increasing or decreasing the DNA mass.
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is the first collection of media containing
viral vectors.
5. Add 16 mL of fresh cell culture medium to
each plate.
6. Put cells back in the incubator at 37C and
3% CO2.
7. Centrifuge two balanced tubes of super-
natants at 250 g for 4 min to remove cell
debris.
8. Repeat with two more balanced tubes of
supernatants (containing approximately
40 mL each).
9. Sterile filter the debris-free superna-
tants using a 0.45 lm filter (approxima-
tely 160 mL of supernatant in total).
Note: Viral particles to be used in pre-
clinical applications should be filtered
through 0.45 micron filters, although 0.22
micron filters are recommended for GMP
manufacturing protocols. Smaller filters
improve purity but can lower the viral
titer.
10. Label this bottle. Wrap the cap with par-
afilm. Keep at 4C overnight.
11. Repeat the following day (second collection
of media containing viral vectors).
Serial ultracentrifugation for viral
vector concentration
 When following the protocol described here in
its entirety, yields of concentrated lentiviral
vector reach physical titers between 1011 and
1012 particles/mL and functional titers be-
tween 107 and 1010 particles/mL. Note that
some transgenes may produce cytotoxicity
during viral production, resulting in lower
viral titers. To overcome this problem, use
of an inducible expression system27 to control
transgene expression during virus production is
recommended.
 GMP manufacturing protocol requires non-
ultracentrifuge-based concentration methods
and more extensive filtration (Table 8) such
as commercially available tangential flow fil-
tration systems, which could be used to pro-
cess the GMP viral material.
1. Place conical adaptors into SW28 buckets
and SW28 tubes into conical adaptors.
2. Use 30 mL ultracentrifuge tubes (Beckman).
3. Place 24 mL of collected cell culture super-
natant in each tube (from day 1 collection).
4. Centrifuge in SW28 at 67,684 g for 2 h at
room temperature.
5. Discard supernatant and replace tubes
into buckets.
6. Place 24 mL of collected cell culture super-
natant in each tube (from day 2 collection).
7. Centrifuge in SW28 at 67,684 g for 2 h at
room temperature.
8. Discard supernatant and keep tubes in-
verted.
9. Aspirate media off the edges of tubes.
10. Re-suspend the pellet with 4 mL of Hank’s
Balanced Salt Solution (HBSS):
a. Add 2 mL in the first tube and wash the
five subsequent tubes.
b. Add 2 mL in the first tube and again
wash the five subsequent tubes.
11. Load 4 mL of HBSS on top of 2 mL of 20%
sucrose in dPBS.
12. Use 6 mL quick-seal tubes (Beckman). Add
HBSS to complete fill.
13. Centrifuge in SW41 at 75,418 g for 1 h at
room temperature.
14. Discard supernatant and aspirate any re-
maining media at edge of tube.
15. Re-suspend the pellet gently in 100lL of
HBSS. Avoid formation of bubbles.
16. Place viral suspension into a low-bind
Eppendorf tube.
17. Re-suspend remaining pellet gently in
100lL of HBSS. Avoid formation of bubbles.
18. Add viral suspension into the same Ep-
pendorf tube (200lL total).
19. Seal tube with parafilm.
20. Shake tube on vortex at low speed for
30 min at room temperature.
21. Spin at 4000 g for 10 s to collect the virus-
containing liquid.
22. Make twenty 10lL aliquots of the virus
and store at -80C.
Troubleshooting
Guidance on troubleshooting is given in Table 6.
GMP considerations involving manufacture
of lentiviral vectors for clinical use
Premises.
 Premises should be clean, in good repair, for
dedicated use, and secure. Conditions such as
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lighting, temperature, and humidity should
be controlled within appropriate parameters
so as not to affect the medicinal products or
starting materials.
 Premises must be designed and controlled to
ensure an aseptic environment for manu-
facturing of ATMPs. GMP procedures and
practices must be in place for ATMPs, as ster-
ilization of the finished product is not an option.
 Positive pressure is used to process sterile
products for aseptic manufacturing. Pressure
cascades should be clearly defined and moni-
tored with alarms.
 Clean areas should be supplied with air which
has passed through filters of an appropriate
efficiency. Clean air devices should be classi-
fied in accordance with ISO 14644-1.
 The Quality Management System of the GMP
manufacturing facility must include an emer-
gency plan dealing with accidental release of
viable organisms. The plan should describe
procedures for containment, ensure the pro-
tection of personnel, and describe means of
decontamination.
 Offices, restrooms, storage space, and labo-
ratory animal laboratories should be separate
from the manufacturing and testing areas.
Manufacturing and testing areas should be
separate from each other as well, with these
procedures carried out by separate personnel.
 Quality control (testing) laboratories must be
Good Laboratory Practice (GLP)-approved
laboratories for assessing titer, sterility, rep-
lication incompetence, and other validation
testing. Efficacy tests such as protein expre-
ssion and functionality after gene delivery in
relevant cells or tissues does not have to occur
at GLP grade and can occur in standard ac-
ademic research labs.
HEK293T producer cells.
 GMP-grade producer cell lines for viral vector
manufacture should be sourced from a suit-
able facility such as the American Type Cul-
ture Collection (ATCC) and maintained as a
Master Cell Bank (MCB). The cell line can
then be expanded and tested to be used as a
certified Working Cell Bank (WCB). Doc-
umentation should be provided for receipt
and storage of these starting materials.
 Establishment of seed lots and cell banks,
including master and working generations,
should be performed under appropriate con-
ditions. This should include an appropriately
controlled environment to protect the seed lot
itself, the cell bank being produced, and the
personnel handling these materials.
 During the establishment of the seed lot and
cell bank, no other living or infectious mate-
rial (e.g., viral vectors or cell lines) should be
handled in the same area or by the same
workers.
 Once a HEK293T cell bank is licensed from
ATCC or sub-licensed from a contract
manufacturing organization, this resource
must be maintained to GMP standards, and
must be certified free of mycoplasma and
adventitious agents such as bacteria and
fungi. Further, this cell line must be vali-
dated, including genotyping for identity ver-
Table 6. Trouble-shooting guide
Problem Possible reason(s) Solution(s)
Low viral titer Low transfection efficiency  Prepare fresh BBS 2· solution
 Purify fresh plasmids
 Re-determine best CaCl2 concentration using the same cell line used for
lentivirus manufacture
 Addition of 6lM of sodium butyrate up to 24 h after transfection may improve
efficiency
HEK293T cells are late-passage or over-confluent  Only use low passage (<20) and healthy HEK293T cells, and make sure they are
around 70% confluent on the day of transfection
Transgene causes toxicity  Use an inducible expression system to control transgene expression during
virus production
Non-optimal storage conditions  Viral preps should be stored at -80C and thawed immediately prior to use
Contamination  Prepare reagents freshly and ensure they are sterile-filtered
 Reanimate a fresh vial of HEK293T and check for adventitious agents
 Purify fresh plasmids
 Check for mycoplasma
 Evaluate aseptic procedures in tissue culture hood
BBS, borate-buffered saline.
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ification and testing for the presence of hu-
man viral contaminants.
 Specific considerations for safety during viral
manufacture include the risk of biological
agents within the HEK293T human-derived
cell line used for production, including blood-
borne viruses: HIV, hepatitis B virus (HBV),
hepatitis C virus (HCV), and hepatitis D virus
(HDV). These are all dangerous pathogens,
which can cause serious or fatal infectious
diseases and cancers. HIV causes acquired
immune deficiency syndrome (AIDS), while
HBV, HCV, and HDV can cause hepatitis, li-
ver cirrhosis, and cancer. While the HEK293T
producer cell line has been used for decades
with no known pathogens, the MCB acquired
from ATCC and any WCBs derived from it
may need further testing to validate the ab-
sence of pathogens. These cells can be safely
disposed after use, upon exposure to a deter-
gent such as TriGene, which destroys bacte-
ria, fungi, and viruses.
 Documentation should be logged and made
available to support traceability, including the
number of generations (e.g., passages) between
the seed lot or cell bank, the storage conditions,
stability data, and recovery logs. These should
be consistent with specifications in the mar-
keting authorization/clinical trial authoriza-
tion, and any deviations should be recorded.
 Cell banks should be stored and recovered in
such a way as to minimize the risks of con-
tamination (e.g., stored in sealed vials in liq-
uid nitrogen vapor).
Transfer and packaging plasmids.
 The transfer vector plasmid contains the gene
of interest (the transgene) with expression
driven by a promoter sequence. Advice should
be requested from the relevant regulatory
authority regarding the subtype of lentivector
transfer plasmid used. The type of vector used
for preclinical studies and clinical-grade
manufacture should be the same. The pro-
moter and transgene sequence should be as
close as possible to the final version.
 The lentivector transfer plasmid used for
preclinical studies may also contain an am-
picillin resistance gene or other selection
marker for amplification in competent bacte-
ria and other elements necessary for effective
infection and gene delivery. Advice should be
requested from the relevant regulatory au-
thority regarding any restrictions on using a
selection marker in the clinical-grade transfer
plasmid. Guideline documents from the Eu-
ropean Medicines Agency indicate that all
beta-lactam antibiotics, such as ampicillin,
and streptomycin should be avoided during
virus production, as they are known to pro-
voke sensitivity in certain individuals.
 The transfer plasmid often includes a fluores-
cent reporter gene, separated from the target
gene by a cleavage site or internal ribosomal
entry site, to identify cells that have been tar-
geted in order to verify the extent of viral
transduction. It may be useful to have this
reporter tool for preclinical testing, but it is
advisable to remove this gene for the purposes
of viral manufacture for clinical applications
because these proteins may be immunogenic.24
 The transfer vector plasmid and the packag-
ing plasmids used for clinical-grade viral
vector manufacture should be amplified un-
der GMP conditions. ‘‘High-quality’’ amplifi-
cation may be suitable for early-phase (e.g.,
first-in-human) clinical investigation. The
plasmids must be certified free of endotoxin
and adventitious agents. Further, the trans-
fer plasmid and packaging plasmids should be
fully sequence verified.
 Documentation should be logged and made
available to support traceability, including
the source of the plasmids, any testing con-
ducted on the plasmids, and the storage con-
ditions. These should be consistent with
specifications in the marketing authorization/
clinical trial authorization, and any devia-
tions should be recorded.
 The third-generation lentiviral vector system
has a major safety advantage compared to
previous systems, but this comes with a cost.
Lower titers are generally obtained in third-
generation compared to second-generation
lentivirus manufacture system due to the
higher number of separate plasmids (four in-
stead of three, respectively) that must be
successfully co-transfected to produce func-
tional particles. Stable inducible packaging
cell lines for lentiviral vectors have been
proposed to overcome this problem.28,29 These
cell lines are capable of producing higher
amounts of vectors by expressing all lentiviral
components at high levels within the cells.
This method would also reduce the costs for
scaled-up lentiviral manufacture, offering an
additional benefit for clinical applications.
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 When changing the components or manu-
facturing process during a transition to
GMP, safety issues must be considered for
the altered vector system. It is recommended
that such changes occur early during tran-
sition to clinical-grade production of the
gene therapies, as these can impact costs
and regulatory considerations.
Reagents and consumables.
 Many of the consumables (e.g., flasks or con-
ical tubes) used in preclinical production may
not necessarily be suitable for the scaled-up
GMP manufacture. However, the standards
for consumables may be met by purveyors of
commonly used laboratory consumables.
 A GMP-grade reagent sourcing form should
be created and used to order items and to
record lots received. This process will ensure
that raw materials can be traced to facilitate
recall of products if necessary.
 Starting materials should be confirmed for
release by quality control personnel before
use in GMP manufacture. All incoming ma-
terials should be checked to ensure the lot
corresponds to the order. All materials re-
ceived must be logged.
 All starting materials should be stored under
appropriate conditions and in an orderly
fashion to permit batch segregation and stock
rotation. Starting materials should be appro-
priately labeled.
 Labels applied to containers, equipment or
premises should be clear and unambiguous.
The format of labeling should be consistent
throughout the facility and should include
status (e.g., quarantined, accepted, or rejected).
 GMP manufacturing procedures must protect
the product and the starting materials from
the risk of contamination, within the accepted
bioburden level described in the marketing
authorization or clinical trial authorization.
 Where sterilization of starting materials is re-
quired, it should be carried out by heat if pos-
sible. Alternatively, other appropriate methods
such as irradiation and filtration can be used
for inactivation of biological materials.
 If plasmid and/or host-cell DNA persists in
the medium, virus-rich supernatants can be
treated with bacterially derived DNase or al-
ternatively with Pulmozyme, a human DNase
approved for human use by the Food and
Drug Administration.30 Pulmozyme treat-
ment would provide a DNase with human
rather than animal origin, but could signifi-
cantly increase the cost of viral vector pro-
duction and could potentially require an
additional step during downstream proces-
sing to remove the enzyme.
 Ensure all reagents have a certificate of
analysis.
 Ensure all reagents have an EDQM designa-
tion (if applicable).
 Ensure all reagents are traceable from point
of origin.
 If a reagent has an animal or human origin,
additional scrutiny may apply. For example,
use of fetal calf serum in cell culture is com-
mon, especially for supporting the mainte-
nance of HEK293T cells used for lentiviral
and AAV production. However, such human-
or animal-derived products must be justified
for use in GMP manufacture; suitable origin
of materials and traceability standards will
apply according to relevant regulatory advice
(e.g., the European Pharmacopoeia). It is re-
commended that non-serum-containing me-
dium is used for GMP purposes.
 As a substitute for small-scale tissue culture
flasks or plates, bioreactors can be packed
with macroporous microcarriers (e.g., Cyto-
pore, Cytoline) then placed in a continuously
stirred tank with circulating medium to
achieve serum-free suspension culture.
Instrumentation and equipment.
 Many preclinical protocols utilize open-
system, small-scale manufacturing. Open-
system manufacturing may be sufficient for
producing high-titer lentivirus for a first-in-
human clinical trial. However, it is sug-
gested that high-throughput closed-system
manufacturing are generally used for GMP
manufacture.
 The equipment (e.g., centrifuges) used in
GMP virus production does not have to be
certified in any particular way, but it does
have to be dedicated to ATMP and not avail-
able for any other use.
 Manufacturing equipment must be ade-
quately maintained. Repair and maintenance
operations should not present any hazard to
manufacturing processes or products them-
selves. Parts of production equipment that
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come into contact with the product must not
react with the product in any way that would
affect the quality of the product.
 All equipment must be cleaned to prevent
contamination, and cleanings should be docu-
mented. Single-use disposable material should
be used wherever possible. Sterilization of
multi-use equipment in contact with the prod-
uct must be validated.
 Equipment should be calibrated and/or in-
spected by appropriate methods at defined
intervals to ensure proper performance, and
these checks should be documented.
 Defective equipment should, if possible, be
removed from production and quality control
areas, or at least be clearly labeled as defec-
tive.
 Many scaled-up cell culture systems are
disposable, single-use bioreactors to achieve
closed-system processing. While this presents
a significant advantage over flasks (which are
limited in scale) or stainless steel containers
(which require cleaning), single-use bioreactors
have greater cost and environmental impact. In
addition, the materials used in any disposables
must be validated, including: the potential for
leaks, the presence of leachables and extract-
ables, the contact time with biological material,
and any changes in risk due to temperature.
 It may be better to make the switch to closed-
system manufacturing early in the translational
process, so that process development concerns
can be addressed during early phases in the
project, and batch testing data can be used to
specify the parameters to be met by future
batches intended for authorized clinical use.
 Table 7 describes several options for scaled-
up closed-system manufacturing using biore-
actors for the growth of cells and collection of
supernatant.
 Table 8 describes several options for tangential
flow filtration as a scaled-up GMP-compatible
method of purifying and concentrating viral
particles.
Manufacturing runs.
 Prior to beginning a production run, it should
be ensured that premises, equipment, and
cell lines are in suitable conditions for GMP
manufacturing.
 At every stage of processing, products and
materials should be protected from microbial
and other contamination.
 Generally ATMPs cannot be terminally ster-
ilized. Therefore, manufacturing of the active
substance and the finished product is re-
quired to be conducted in appropriate condi-
Table 7. Equipment for scaled-up GMP lentiviral manufacture
Supplier Model Features Advantages Scale
Biotek 3D Perfusion Bioreactor 4 independent, autoclavable polycarbo-
nate chambers. Cell culture medias
are perfused through the open porous
structure of scaffolds using a pulsatile
pump.
3D Insert scaffolds with various sizes
ranging from 96-well to 6-well. Can
be used as a single-use bioreactor
system.
Small-scale
Corning CELLSTACK Culture
Chambers
Cell yields in the 107–109 range and are
useful alternatives to multiple roller
bottles or spinner flasks.
A more hydrophilic surface giving more
consistent, even cell attachment, in-
creased cell growth and yields.
200mL, 1 L, 2 L, or 8 L
Terumo Quantum Bioreactor This hollow-fiber bioreactor system al-
lows seeding of producer cells on
high-surface areas using small vol-
umes for continuous flow.
High yields with a small footprint. 2.1 m2
Surface area occupying a total volume of
180 mL
Sartorius l-bioreactor (small-scale)
to BIOSTAT (large-scale)
Bioreactor platform from cell line devel-
opment to commercial manufacturing.
Simple transition between scales. 15mL (MBR) or 2,000 L (BIOSTAT)
Pall iCELLis A closed-system, fully integrated, single-
use, fixed-bed bioreactor, which uses
microcarriers to immobilize continu-
ously perfused cells.
Excellent large-scale production, and
simple transition between scales. No
oxygen sparging required.
1–70 L in bioreactor; 40 mL to 25 L in
fixed beds with diameters 110–
860mm
GE Xcellerex XDR-10 A closed-system, fully-integrated, single-
use bioreactor which uses microcar-
riers to immobilize continuously-
perfused cells.
Excellent large-scale production. Auto-
mated data management, low-shear
impeller for gentle efficient mixing of
medium.
4.5–10 L, available in single, twin, triple,
and quad vessel configuration
GMP, Good Manufacturing Practice.
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tions to ensure aseptic manufacturing. For
non-sterile raw or starting materials, addi-
tional steps may need to be taken to ensure
subsequent aseptic manufacturing (e.g., ster-
ile filtration of raw materials or irradiation).
 Measures to prevent cross-contamination ap-
propriate to the risks identified should be put
in place. The manufacture of viral vectors
and gene therapy medicinal products should
be separated spatially and temporally from
other products.
 When seeking a contract manufacturing orga-
nization as a partner for GMP manufacture of
the clinical-grade product, it may be useful to
query not only the platform technologies and
manufacturing processes used, but also whe-
ther any other products are being concurrently
manufactured in the same space. These other
products may cause concern regarding multi-
product manufacture within the same facility.
 Procedures for maintaining facility infrastruc-
ture, logging resources, maintaining equipment,
documenting procedures, training staff, prac-
ticing waste disposal, reporting to regulatory
bodies, and carrying out internal and external
audits must be in place prior to production,
as well as procedures for quality control and
quality assurance.
Virus production.
 Before any processing operation is started,
steps should be taken to ensure that the work
area and equipment are clean and free from
any starting materials, products, product
residues, or documents not required for the
current operation.
 Centrifugation of products can lead to aerosol
formation and containment of such activities
to minimize cross-contamination is necessary.
 The growth-promoting properties of culture
media should be demonstrated to be suitable
for its intended use. If possible, media should
be sterilized in situ. In-line sterilizing filters
for routine addition of gases, media, acids or
alkalis, anti-foaming agents, and so on to
bioreactors should be used where possible.
 Addition of materials or cultures to fermenters
and other vessels and sampling should be
carried out under carefully controlled condi-
tions to prevent contamination. Care should be
taken to ensure that vessels are correctly con-
nected when addition or sampling takes place.
 The gene therapy itself and its clinical appli-
cation should be described in the Investiga-
tional Brochure. Details on manufacturing
and testing of the viral gene therapy and the
raw materials that go into it (e.g., reagents,
plasmids, and producer cell line) should be
made available through the Investigational
Medicinal Product Dossier (IMPD).
 Many of the reagents used in preclinical lenti-
virus manufacture are made or sterilized under
high-quality conditions, traced from origin, and
certified for GMP use. Any human- or animal-
derived products (e.g., serum-containing media)
that are used in gene-therapy production (e.g.,
with adherent cell cultures) must be justified
for use in GMP manufacture. Suitable origin of
materials and traceability standards will apply.
Alternatively non-serum-containing medium
can be used in scaled-up bioreactor settings to
achieve high-volume production for GMP pur-
poses.
 For both preclinical and GMP manufacture,
HEK293T producer cells can be transiently
transfected to allow packaging of the viral
vector containing genetic payload. In this
protocol, the affordable and efficient method
of calcium phosphate co-precipitation is used,
Table 8. Commercially available tangential-flow filtration (TFF) systems for lentivirus particles concentration
Supplier Product Features References
GE Healthcare Life
Sciences
UniFluxTM system with a 750 kDa hollow-
fiber ultrafiltration cartridge
Available in four sizes (5–600 L) Merten et al.17;
Ausubel et al.16Fully automated
Single-use cartridges
Real-time data logging and reporting
function
Spectrum Laboratories KrosFlo Research II TFF System Volumes ranging from 1mL to 10 L Cooper et al. 201131
Automated process control and data
collection software
Pall Minim with a Centramate LV holder and
a 100 or 300 kDa Omega Screen
channel-cassette
Scalable Geraerts et al. 200532
Ready-to-use
Semi or full automation
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although other proprietary methods can be
used. Stable cell lines used for production
must be specified to the regulatory authori-
ties, including any viral vectors used and the
raw materials used in their production.
 Ultracentrifugation is commonly used to con-
centrate lentiviral particles for preclinical ap-
plications in gene delivery particularly for
in vivo applications.33 This is the efficient and
easy method for concentrating viral particles
for preclinical assays used in this protocol. Al-
ternative protocols such as diafiltration and
tangential flow provide options for spin-free
protocols to reduce risks to GMP compliance.
Tangential flow can be used for purification,
concentration, and desalting for GMP purposes.
 The final formulation in which the viral parti-
cles are re-suspended may be a buffered salt
solution or suitable alternatives. Any use of
growth media, supplements, transfection re-
agents, and resuspension media during man-
ufacture must be documented and justified in
the IMPD.
Documentation of procedures and materials
Documentation allows the recording of quality
controls, aids quality assurance, and provides evi-
dence to support batch release. The goal of docu-
mentation is to establish, control, monitor, and
record all materials and activities which directly
or indirectly may affect the quality of medicinal
products.
 All calibration and cleaning of equipment and
instruments must be documented.
 All handling of materials and products, such
as receipt and quarantine, sampling, storage,
labeling, dispensing, processing, packaging,
and distribution, must be documented.
 All reagents, producer cells, plasmids, and vi-
ral vectors must be documented (see Table 9).
 Documentation for manufacturing and testing
may be paper-based or electronic, and a data
management plan should be in place. Shadow
copies allow data to be retrieved if accidentally
deleted. Facility management must ensure
that any servers containing documentation are
housed in temperature-controlled room with
restricted access and with redundant power
supply. Data should be backed up regularly to
a mirrored server in a separate building.
 Batch documentation should be kept for 1
year after expiry of the batch to which it re-
lates or at least 5 years after certification of
Table 9. Process for documenting lentiviral
production under GMP
GMP documentation required for reagents
Name of material.
Identity of original supplier and manufacturer
Product code
Product origin
Manufacturer’s batch number or lot number
Amount of material received
Date material was received
Storage and transport conditions
Maximum shelf life
Quality requirements and acceptance criteria
Status (e.g., in quarantine, being tested, released, rejected)
Raw materials of biological origin: contracts, certificates of analysis, and quality
requirements agreed with third-party suppliers.
GMP documentation required for producer cells
Name of cell line
Identity of original supplier
Batch number from expansion of master cell line
Passage number from expansion of master cell line
Date that cells were passaged for use
Identity of person passaging cells for use
Identity of person checking operations
GMP documentation required for plasmids
Name of plasmid product
Identity of original supplier
Traceability records from sourcing of starting reagents
Dates for starting and completing production
Dates for starting and completing testing
Product yield and batch number of each plasmid
Identification (initials) of the operator of each step
Identification (initials) of the person checking operations
Results of the relevant quality control tests
Storage and transport conditions
Maximum shelf life
GMP documentation required for viral vectors
Name of viral product
Batch number
Batch definition
Quantities of each starting material
Batch number of each starting material
Traceability records from sourcing of starting reagents
Dates for starting and completing production
Dates for starting and completing testing
Product yield and batch number of each viral batch
Identification (initials) of the operator of each step
Identification (initials) of the person checking operations
Manufacturing order (e.g., written request to start manufacturing a batch)
Manufacturing instructions (e.g., SOPs for batch production and testing)
Any deviations from protocol that occurred during production and testing
Product yield obtained at relevant stages of manufacture
Results of sterility assays
Results of titer measurements
Results of replication competency testing
Results of cytotoxicity testing
Results of stability testing
Results of integrity testing
Results of any additional batch release tests
Storage and transport conditions
Maximum shelf life
Instructions for any product preparation (e.g., thawing or dilution procedures)
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the batch by the QP, whichever is longest. For
any investigational medicinal products, the
batch documentation must be kept for at least
5 years after the completion or formal dis-
continuation of the last clinical trial in which
the batch was used.
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